Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
|Articles|September 16, 2021
Pharmacy Clinical Pearl of the Day: Multiple Sclerosis
Author(s)Saro Arakelians, PharmD
In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers, causing deterioration of the nerves.
Advertisement
Clinical Pearl of the Day: Multiple Sclerosis
Multiple sclerosis (MS) is a disease of the brain and spinal cord.
Explanation:
- In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers, causing deterioration of the nerves.
- Symptoms of MS include numbness, weakness, tremor, lack of coordination, blurry vision, double vision, slurred speech, fatigues, dizziness, tingling, and problems with bowel and bladder function.
- Diagnosis could include blood test, spinal tap, MRI, and an evoked potential test.
- Treatment options may include Interferon beta, Copaxone, Gilenya, Tecfidera, Vumerity, Aubagio, Mayzent, Mavenclad, Ocrevus, Tysarbi, Lemtrada, and physical therapy.
References
Advertisement
Related to this article
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
Biologic Stewardship: The Next Frontier for Health System Pharmacists
5